Production of recombinant adeno-associated virus vectors

• US 5,173,414 A
• Filed: 10/30/1990
• Issued: 12/22/1992
• Est. Priority Date: 10/30/1990
• Status: Expired due to Term

• Current Assignee: Gencell SA (Sanofi )
• Original Assignee: Applied Immune Sciences, Inc. (Sanofi )
• Inventors: Lebkowski, Jane S., Okarma, Thomas B., McNally, Maureen A.
• Primary Examiner(s): Schwartz, Richard A.
• Assistant Examiner(s): MOSHER, MARY
• Application Number:
  US07/605,775
• Time in Patent Office: 784 Days
• Field of Search: 435/320.1, 435/172.3, 435/235.1, 435/69.1, 935/32, 935/34, 935/57, 935/27, 935/56
• US Class Current: 435/91.4
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/16244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
• CPC Class Codes: C12N 2710/16262 by genetic engineering
• CPC Class Codes: C12N 2750/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

A simplified method to produce recombinant adeno-associated virus (AAV) vectors is described. The procedure involves the use of chimeric plasmids which incorporate the Epstein Barr nuclear antigen (EBNA) gene, the latent origin of replication of Epstein Barr Virus (oriP), and a recombinant AAV genome. The chimeric plasmids themselves are also a part of the present invention. These EBV/AAV plasmids are maintained as multicopy extra-chromosomal elements in cells, such as human 293 cells. Permanent cell lines carrying these EBV/AAV plasmids are induced to produce large amounts of recombinant AAV virus upon addition of wild-type, adeno-associated virus helper functions. Recombinant AAV vectors produced in this manner are capable of transducing exogenous genes into other human cell lines and exhibit all of the attributes of viral elements produced by conventional methods.

Claims

1. A recombinant plasmid vector, comprising in the order given in the 5'"'"'-3'"'"' direction:

an Epstein Barr nuclear antigen (EBNA) gene, an Epstein Barr virus (EBV) latent origin of replication (oriP), and a recombinant adeno-associated virus (AAV) transducing vector comprising exogenous genetic material and lacking a functional AAV rep gene.

2. The vector of claim 1, wherein said plasmid vector comprises a detectible genetic marker.

3. The vector of claim 2, wherein said genetic marker is an antibiotic resistance gene.

4. The vector of claim 3, wherein said antibiotic resistance gene is located in said AAV vector.

5. The vector of claim 3, wherein said antibiotic resistance gene is located in said plasmid vector outside said AAV vector.

6. The vector of claim 1, wherein at least two genetic markers are present in said plasmid vector, an antibiotic resistance gene in said AAV vector and a second genetic marker located in said plasmid vector outside said AAV vector.

7. The vector of claim 1, wherein said AAV vector further lacks a functioning structural capsid gene segment.

8. The vector of claim 1, wherein said recombinant AAV vector comprises a selectable marker gene and two or more exogenous genes.

9. A method for producing AAV vectors, which comprises:

cloning a preformed AAV transducing vector containing exogenous genetic material into an EBV plasmid, wherein said EBV plasmid comprises an EBNA gene, an oriP DNA fragment, and a detectible genetic marker;

transfecting a host cell line with the resulting EBV/AAV chimeric plasmid to produce a transfected cell line;

growing said transfected cell line in a cell growth medium;

contacting said transfected cell line with adenovirus and wild-type adeno-associated virus helper functions; and

isolating said AAV vector from said cell growth medium.